Antifungal Treatment Market Size, Emerging Technologies, Comprehensive Analysis, Future Prospects, Regional Trends And Potential Of The Industry 2023

Posted January 2, 2020 by Sapanas

Global antifungal treatment market is expected to grow at a CAGR of 4.61% during the forecast period and is estimated to reach USD 19,558.0 million by 2023.

Antifungal Treatment Market Overview

Global antifungal treatment market is expected to register a CAGR of 4.61% and attain a valuation of USD 19,558.0 Mn by the end of the forecast period of 2017-2023, projects Market Research Future (MRFR) in a detailed study.

Surging prevalence of fungal infections is the prime drive behind the growth of the global antifungal treatment market. People across the globe are afflicted by severe fungal infections such as cryptococcosis, candidiasis, aspergillosis, and pneumocystosis which can be life-threatening. Fungal infections have risen dramatically in recent years which has generated high demand for diagnosis and treatment consequently boosting the growth of the global antifungal treatment market.

Motivated by the alarming rise in fungal infections and a strong need for effective antifungal compounds, there has been extensive research & development on new antifungal compounds have resulted in the development of new antifungal agents. This coupled with increasing government support for R&D activities create a supportive dais for the growth of the global antifungal treatment market.

Various programs have been initiated across the globe to reduce fungal illness and deaths associated with fungal diseases worldwide and to educate healthcare professionals regarding the same which has further propelled the growth of the global antifungal treatment market.

A rise in the number of FDA approvals for antifungal drugs is expected to lead growth in the global antifungal treatment market. Other driving factors include the availability of new drugs, growing awareness regarding the side effects of traditional remedies and rise in geriatric population.

Avail Free Sample Copy at

Antifungal Treatment Market Segmentation

The global antifungal treatment market has been segmented based on drug class, therapeutic indication, pathogen, and end user.

By drug class, the global antifungal treatment market has been segmented into azoles, echinocandins, polyenes, pyrimidines, allylamines, and others drugs. The Azoles segment held the largest market share in 2016.

By therapeutic indication, the global antifungal treatment market has been segmented into systemic, coccidioidomycosis, candidiasis, and cryptococcosis. The systemic segment was the largest segment in 2016.

By pathogen, the global antifungal treatment market has been segmented into Candida, Cryptococcus, Coccidioides immitis, Aspergillus, Zygomycetes, Trichophyton, and others.

By end user, the global antifungal treatment market has been segmented into hospitals & clinics, dermatology clinics, and other users.

Antifungal Treatment Market Regional Analysis

The Americas, Asia Pacific (APAC), Europe, and the Middle East & Africa (MEA) are the key markets for antifungal treatment.

The Americas is account for the lion's share of the global antifungal treatment market driven by the widespread prevalence of fungal infections in the region, high healthcare expenditure, and availability of advanced treatment options.

Europe is the second largest market for antifungal treatment and is expected to grow significantly over the forecast period. High investment in R&D activities, availability of skilled medical professionals, increasing healthcare expenditure and surging prevalence of fungal diseases in the region.

Antifungal Treatment Market Competitive Landscape

The key players in the global antifungal treatment market include Novartis AG (Switzerland), Merck & Co., Inc. (U.S), Pfizer Inc. (U.S), Bayer AG (Germany), Astellas (Japan), and Sanofi (France).

Antifungal Treatment Industry Updates

In December 2018, The US Food and Drug Administration (FDA) approved SUBA-itraconazole (Tolsura), an antifungal indicated for the treatment of systemic fungal infections. The SUBA-itraconazole can be used in the treatment of blastomycosis, aspergillosis, and histoplasmosis.

In January 2019, F2G Ltd, a biotech company focused on developing therapies for life-threatening fungal infections, raised funding of EUR 24 Million loans from the European Investment Bank (EIB). The company also raised funding from life science investor Morningside Venture Investments Ltd. (Morningside). The funding would be utilized by the company to expedite its worldwide Phase 2b study on invasive fungal infections.

Browse Complete Report with TOC at
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By Sapanas
Phone 6468459312
Business Address Market Research Future Office No. 528, Amanora Chambers Magarpatta Road, Hadapsar, Pune - 411028 Maharashtra, India
Country India
Categories Health , Industry , Medical
Tags Antifungal Treatment Market , Antifungal Treatment Market Size , Antifungal Treatment Market Share , Antifungal Treatment Market Growth , Antifungal Treatment Market Analysis , Antifungal Treatment Market Trends , Antifungal Treatment
Last Updated January 2, 2020